Emicizumab is a bispecific моноклональный антитело that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.